Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Xylose, also known as D-Xylose, comes from hemicellulose found in plants. In the pharmaceutical world, this sugar finds its place as a raw material for a range of drug formulations, medical tests, and as a base for chemical synthesis. Chemically, its identity roots in its formula: C5H10O5, building a foundation for many applications that demand high purity, safety, and consistency.
At the molecular level, Xylose falls among the pentoses, notching five carbons in its backbone. The straight-chain version easily shifts into a ring structure in solution, which impacts both solubility and reactivity. These ring and straight forms can show up in different scenarios within pharmaceutical work. The molar mass lands at about 150.13 g/mol, a detail that matters for dosing and chemical calculations. Its crystalline form echoes the neat order of its internal bonds. The density sits at around 1.52 g/cm3, offering a reliable measure for handling in any standard laboratory or production facility.
Xylose presents as a white, crystalline solid, although powder and pearl (granular) forms also show up in supply chains. Rarely, one might see a syrup or solution, but these are uncommon in pharma work. The solid’s clean look signals purity—important for sensitive drug applications. The melting point lands around 144-146°C. Purity usually exceeds 98%, which aligns with strict pharmacopoeia standards from BP, EP, and USP. Water solubility proves key: Xylose dissolves easily, supporting fast mixing for analytical or product development work.
On trade papers and import documents, Xylose claims the HS Code 2940.00, marking it as an organic compound not elsewhere specified. This number allows for easier clearance across borders in the global pharmaceutical market, especially in a world where ingredient traceability demands more transparency every year. Supply starts with agricultural byproducts—usually hardwoods, corn cobs, or straw—then purification climbs through several steps. Every batch hooks up with documentation that details country of origin, batch quality, and regulatory alignment.
Xylose is generally safe as a food ingredient and remains non-toxic at the exposures found in pharma manufacturing. Exposure limits aren’t as restrictive as other chemicals in the lab. Still, handling any pure sugar dust, even D-Xylose, calls for care: avoid inhaling fine powder or letting it sit around to prevent dust explosions. Those working daily with Xylose should keep it tightly sealed, stick to standard protective gloves, and avoid direct skin or eye contact. Spills clean up with simple water and a mop. According to available data, the material poses no chronic hazards, though every worker ought to check the latest safety sheets to confirm there are no new findings.
As a reducing sugar, Xylose can play into redox reactions. This means it reacts in certain colorimetric assays and can take part in Maillard-type reactions if exposed to amino acids and heat, relevant for folks working in formulation labs or in dietary testing. In solution, its stability holds at room temperature under neutral pH, and it resists breakdown far better than many alternatives. Even though it’s a sugar, its metabolic path in humans avoids most common enzymatic routes, which is why clinicians sometimes use it for absorption testing.
Suppliers pack pharma-grade Xylose in multi-kilogram bags, fiber drums, or high-density plastic pails, usually lined with food-grade film. Typical grain sizes hover between fine powder and medium crystals, never letting clumping become an issue. Lab-scale operations prefer smaller, easily poured containers; commercial scale customers—such as large pharmaceutical formulators—lean toward bulk shipments loaded into automated feeders. Flake and pearl forms stay rare in this sector, though they sometimes fill a need for slow flow in continuous production lines.
Biopharmaceutical manufacturing leans on Xylose’s predictable behavior in formulation. Oral and parenteral products can rely on its inert profile. In research hospitals, the D-Xylose absorption test stands out as a diagnostic for malabsorption issues, since human intestines can’t break down or digest it through normal pathways. As a result, a simple urine or blood test after Xylose intake gives doctors clear insight into a patient’s digestive health. In fermentation labs, the sugar sometimes serves as feedstock for specialty microbe cultures aimed at producing xylitol, an alternative sweetener, or for synthetic pathways chasing specialty polyols or derivatives.
Supply chain stability hits as a top concern, drawn from personal experience in working with global ingredient distributors. Agricultural fluctuations, weather patterns, and shifting demand tie directly to spot prices and availability of high-purity grades. Any shortage forces pharma producers to scramble, especially those running on just-in-time models. On top of that, regulatory changes can ripple across the globe, especially as agencies tighten up rules on traceability for every chemical entering a plant. The best remedy combines long-term relationships with vetted suppliers, ongoing quality checks, and a willingness to keep safety stocks in secure, climate-controlled storage.
New technologies—enzymatic purification, green chemistry routes to xylosides—offer hope for even cleaner, more reliable production. Open disclosure of each step, enabled by robust blockchain or digital ledger tech, builds trust for pharma buyers and ensures patient safety downstream. As medicine grows more sophisticated, the need for consistent, traceable, and clearly described raw materials such as Xylose will keep rising. Researchers and formulators have a responsibility to document and communicate material properties not only in dense regulatory filings, but in everyday product descriptions and specs that allow anyone in the supply chain to understand what they’re holding and how to use it safely.
Chengguan District, Lanzhou, Gansu, China
